PharmaGraphX

Log in Get Started

Secukinumab

Cosentyx

Monoclonal antibody

Standard

Half-life

22-31 days

Protein Binding

N/A

Metabolized By

N/A

External

Drugs.com

Mechanism of action

Human monoclonal antibody that selectively binds and neutralizes IL-17A

Recorded indications

From the drug index — may include conditions studied rather than approved indications

·Giant Cell Arteritis
·Polymyalgia Rheumatica
·Hidradenitis Suppurativa
·Giant Cell Arteritis (GCA)
·Takayasu Arteritis

Interactions

No curated interaction pairs are recorded for Secukinumab. This is not a statement that none exist — check a full interaction reference before combining.

Common adverse effects

Nasopharyngitis
Diarrhea
Upper respiratory infections

Pharmacokinetics

Half-life: 22-31 days
Protein binding: N/A

Pregnancy & lactation

Not recorded for Secukinumab. Absence here means this database does not hold a category — not that the drug is safe in pregnancy or breastfeeding.

Sources

Assembled from: drug index, curated drug database.

Not a substitute for clinical judgement